BIVI insider filings
BIOVIE INC. — 47 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-08-28. Screen BIVI transaction legs live →
Insider transaction summary — last 90 days
2026-07-10 to 2026-10-08, from the filings listed below: 4 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 4 legs across 4 filings by 4 insiders — 23,280 shares, $49,118 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 15,210 shares @ $2.08 ($31,637) by DO CUONG V, filed 2026-08-28.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| DO CUONG V — President & CEO, Director | 1 | 1 leg · 15,210 sh · $31,637 | — | — |
| Palumbo Joseph M — Chief Medical Officer | 1 | 1 leg · 4,843 sh · $10,461 | — | — |
| KIM JOANNE WENDY — Chief Financial Officer | 1 | 1 leg · 2,500 sh · $5,450 | — | — |
| Chappell Amy Suzon — Director | 1 | 1 leg · 727 sh · $1,570 | — | — |
Recent insider filings — BIOVIE INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-28 | 4 | Palumbo Joseph M — Chief Medical Officer | Purchase (P): 4,843 @ $2.16 | EDGAR |
| 2026-08-28 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Purchase (P): 2,500 @ $2.18 | EDGAR |
| 2026-08-28 | 4 | Chappell Amy Suzon — Director | Purchase (P): 727 @ $2.16 | EDGAR |
| 2026-08-28 | 4 | DO CUONG V — President & CEO, Director | Purchase (P): 15,210 @ $2.08 | EDGAR |
| 2026-01-09 | 4 | Palumbo Joseph M — Chief Medical Officer | Grant/award (A): 132,000 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Grant/award (A): 110,100 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Sherman Michael Edward — Director | Grant/award (A): 80,000 (derivative) @ $0 · Grant/award (A): 341,100 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Farag Kameel D. — Director | Grant/award (A): 57,500 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Chappell Amy Suzon — Director | Grant/award (A): 57,500 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Lang James Paul — Director | Grant/award (A): 90,000 (derivative) @ $0 · Grant/award (A): 330,500 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | DO CUONG V — President & CEO, Director | Grant/award (A): 665,300 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | ROGICH SIGMUND — Director | Grant/award (A): 70,000 (derivative) @ $0 · Grant/award (A): 141,100 (derivative) @ $0 | EDGAR |
| 2025-08-13 | 4 | DO CUONG V — President & CEO, Director | Purchase (P): 5,000 · Purchase (P): 5,000 (derivative) | EDGAR |
| 2025-01-07 | 4 | Sherman Michael Edward — Director | Grant/award (A): 56,900 (derivative) @ $0 · Grant/award (A): 23,325 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Lang James Paul — Director | Grant/award (A): 61,600 (derivative) @ $0 · Grant/award (A): 22,690 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Palumbo Joseph M — Chief Medical Officer | Grant/award (A): 15,417 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Grant/award (A): 14,417 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | DO CUONG V — President & CEO, Director | Grant/award (A): 104,502 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | Hariri Robert J — Director | Grant/award (A): 49,800 (derivative) @ $0 · Grant/award (A): 21,815 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | ROGICH SIGMUND — Director | Grant/award (A): 32,700 @ $0 · Grant/award (A): 22,070 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | BERMAN RICHARD J — Director | Grant/award (A): 34,200 @ $0 · Grant/award (A): 23,155 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | Palumbo Joseph M — Chief Medical Officer | Tax withholding (F): 2,476 @ $5.51 · Tax withholding (F): 2,476 @ $1.18 · Grant/award (A): 116,000 @ $0 · Tax withholding (F): 29,000 @ $0.47 · Grant/award (A): 156,000 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Tax withholding (F): 2,476 @ $5.51 · Tax withholding (F): 2,476 @ $1.18 · Grant/award (A): 73,000 @ $0 · Tax withholding (F): 18,250 @ $0.47 · Grant/award (A): 99,000 (derivative) @ $0 | EDGAR |
| 2024-07-12 | 4 | DO CUONG V — President & CEO, Director | Tax withholding (F): 4,953 @ $5.51 · Tax withholding (F): 4,953 @ $1.18 · Grant/award (A): 168,000 @ $0 · Tax withholding (F): 42,000 @ $0.47 · Grant/award (A): 227,000 (derivative) @ $0 | EDGAR |
| 2024-03-06 | 4 | DO CUONG V — President & CEO, Director | Purchase (P): 10,000 · Purchase (P): 5,000 (derivative) | EDGAR |
| 2023-12-13 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Grant/award (A): 5,000 @ $0 | EDGAR |
| 2023-12-06 | 4 | Lang James Paul — Director | Grant/award (A): 93,500 (derivative) @ $0 | EDGAR |
| 2023-12-06 | 4 | Sherman Michael Edward — Director | Grant/award (A): 89,750 (derivative) @ $0 | EDGAR |
| 2023-12-06 | 4 | Hariri Robert J — Director | Grant/award (A): 42,254 @ $0 | EDGAR |
| 2023-12-06 | 4 | ROGICH SIGMUND — Director | Grant/award (A): 42,254 @ $0 | EDGAR |
| 2023-12-06 | 4 | BERMAN RICHARD J — Director | Grant/award (A): 51,830 @ $0 | EDGAR |
| 2023-12-06 | 4 | GORLIN STEVE — Director | Grant/award (A): 46,358 @ $0 · Sale (S): 75,680 @ $1.69 | EDGAR |
| 2023-12-01 | 4 | DO CUONG V — President & CEO, Director | Purchase (P): 10,000 @ $1.78 | EDGAR |
| 2023-09-07 | 4 | GORLIN STEVE — Director | Sale (S): 8,560 @ $3.05 | EDGAR |
| 2023-08-24 | 4 | BERMAN RICHARD J — Director | Sale (S): 10,805 @ $3.50 | EDGAR |
| 2023-07-03 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | Palumbo Joseph M — Chief Medical Officer | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | DO CUONG V — CEO & President, Director | Grant/award (A): 149,500 @ $0 · Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | DO CUONG V — CEO & President, Director | Option exercise (M): 41,506 · Option exercise (M): 41,506 (derivative) @ $0 | EDGAR |
| 2023-06-15 | 4 | BERMAN RICHARD J — Director | Sale (S): 5,000 @ $6.50 · Sale (S): 5,984 @ $5.81 | EDGAR |
| 2023-04-06 | 4 | BERMAN RICHARD J — Director | Sale (S): 3,371 @ $8.52 · Sale (S): 5,000 @ $8.52 · Sale (S): 2,613 @ $8.52 | EDGAR |
| 2023-02-22 | 4 | KIM JOANNE WENDY — Chief Financial Officer | Tax withholding (F): 2,476 @ $6.12 | EDGAR |
| 2023-02-22 | 4 | Palumbo Joseph M — Chief Medical Officer | Tax withholding (F): 2,476 @ $6.12 | EDGAR |
| 2023-02-22 | 4 | Ahlem Clarence N. — EVP Neuroscience Product Dev. | Tax withholding (F): 2,476 @ $6.12 | EDGAR |
| 2023-02-22 | 4 | MARKHAM PENELOPE — EVP Liver Cirrhosis R&D | Tax withholding (F): 2,476 @ $6.12 | EDGAR |
| 2023-02-22 | 4 | DO CUONG V — CEO & President, Director | Tax withholding (F): 4,953 @ $6.12 | EDGAR |
| 2023-02-22 | 4 | READING CHRISTOPHER — EVP Neuroscience R&D | Tax withholding (F): 2,476 @ $6.12 | EDGAR |
Recent 8-K events — BIOVIE INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-13 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-07-23 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-27 | 8-K | 3.03 — Material Modification to Rights of Security Holders | EDGAR |
| 2025-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2024-11-08 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
Registration filings — BIOVIE INC.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-297552 (S-1) — latest: Amendment (S-1/A), filed 2026-08-14
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BIVI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →